358 related articles for article (PubMed ID: 14992907)
1. Changes in hemostasis during pediatric heart surgery: impact of a biocompatible heparin-coated perfusion system.
Jensen E; Andréasson S; Bengtsson A; Berggren H; Ekroth R; Larsson LE; Ouchterlony J
Ann Thorac Surg; 2004 Mar; 77(3):962-7. PubMed ID: 14992907
[TBL] [Abstract][Full Text] [Related]
2. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients.
Lindholm L; Westerberg M; Bengtsson A; Ekroth R; Jensen E; Jeppsson A
Ann Thorac Surg; 2004 Dec; 78(6):2131-8; discussion 2138. PubMed ID: 15561050
[TBL] [Abstract][Full Text] [Related]
3. Prospective double-arm study of fibrinolysis in surgical patients.
Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
[TBL] [Abstract][Full Text] [Related]
4. Closed cardiopulmonary bypass circuits suppress thrombin generation during coronary artery bypass grafting.
Nakahira A; Sasaki Y; Hirai H; Fukui T; Matsuo M; Takahashi Y; Kotani S; Suehiro S
Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):555-60. PubMed ID: 20061337
[TBL] [Abstract][Full Text] [Related]
5. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
[TBL] [Abstract][Full Text] [Related]
6. Clinical study of biocompatibility between open and closed heparin-coated cardiopulmonary bypass circuits.
Tanaka H; Oshiyama T; Narisawa T; Mori T; Masuda M; Kishi D; Kitou T; Miyazima S
J Artif Organs; 2003; 6(4):245-52. PubMed ID: 14691666
[TBL] [Abstract][Full Text] [Related]
7. Cardiopulmonary bypass parameters and hemostatic response to cardiopulmonary bypass in infants versus children.
Eisses MJ; Chandler WL
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):53-9. PubMed ID: 18249331
[TBL] [Abstract][Full Text] [Related]
8. Biocompatibility of poly2methoxyethylacrylate coating for cardiopulmonary bypass.
Noguchi M; Eishi K; Tada S; Yamachika S; Hazama S; Izumi K; Tanigawa K
Ann Thorac Cardiovasc Surg; 2003 Feb; 9(1):22-8. PubMed ID: 12667126
[TBL] [Abstract][Full Text] [Related]
9. One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery. Effect of aprotinin.
Mannucci L; Gerometta PS; Mussoni L; Antona C; Parolari A; Salvi L; Biglioli P; Tremoli E
Thromb Haemost; 1995 Mar; 73(3):356-61. PubMed ID: 7545317
[TBL] [Abstract][Full Text] [Related]
10. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass.
Chan AK; Leaker M; Burrows FA; Williams WG; Gruenwald CE; Whyte L; Adams M; Brooker LA; Adams H; Mitchell L; Andrew M
Thromb Haemost; 1997 Feb; 77(2):270-7. PubMed ID: 9157580
[TBL] [Abstract][Full Text] [Related]
11. Effect of polymer coating (poly 2-methoxyethylacrylate) of the oxygenator on hemostatic markers during cardiopulmonary bypass in children.
Eisses MJ; Geiduschek JM; Jonmarker C; Cohen GA; Chandler WL
J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):28-34. PubMed ID: 17289476
[TBL] [Abstract][Full Text] [Related]
12. Hemostatic changes and clinical sequelae after on-pump compared with off-pump coronary artery bypass surgery: a prospective randomized study.
Paulitsch FS; Schneider D; Sobel BE; Rached R; Ramires J; Jatene F; Stolf N; Hueb W; Lopes NH
Coron Artery Dis; 2009 Mar; 20(2):100-5. PubMed ID: 19293667
[TBL] [Abstract][Full Text] [Related]
13. Activation of coagulation and fibrinolytic systems in patients with CLI is not normalized after surgical revascularisation.
Pärsson H; Holmberg A; Siegbahn A; Bergqvist D
Eur J Vasc Endovasc Surg; 2004 Feb; 27(2):186-92. PubMed ID: 14718902
[TBL] [Abstract][Full Text] [Related]
14. Strategies to reduce hemostatic activation during cardiopulmonary bypass.
Eisses MJ; Velan T; Aldea GS; Chandler WL
Thromb Res; 2006; 117(6):689-703. PubMed ID: 15996721
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
[TBL] [Abstract][Full Text] [Related]
17. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
[TBL] [Abstract][Full Text] [Related]
18. The use of minimized extracorporeal circulation system has a beneficial effect on hemostasis--a randomized clinical study.
Abdel-Rahman U; Martens S; Risteski P; Ozaslan F; Riaz M; Moritz A; Wimmer-Greinecker G
Heart Surg Forum; 2006; 9(1):E543-8. PubMed ID: 16403712
[TBL] [Abstract][Full Text] [Related]
19. Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility.
Moen O; Fosse E; Dregelid E; Brockmeier V; Andersson C; Høgåsen K; Venge P; Mollnes TE; Kierulf P
Ann Thorac Surg; 1996 Oct; 62(4):1134-40. PubMed ID: 8823102
[TBL] [Abstract][Full Text] [Related]
20. Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits.
Borowiec J; Bagge L; Saldeen T; Thelin S
Thorac Cardiovasc Surg; 1997 Aug; 45(4):163-7. PubMed ID: 9323816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
